Eli Lilly files for NAFTA arbitration in $500M drug patent dispute with Ottawa
Sep 16, 2013 / 2:14 am
OTTAWA - U.S. drug company Eli Lilly has escalated a $500-million patent dispute with the federal government and filed a notice of arbitration under the North American Free Trade Agreement.
The company is demanding compensation for court decisions that invalidated its patents for Strattera, a treatment for attention-deficit/hyperactivity disorder, and for Zyprexa, which is used for the treatment of schizophrenia and bipolar disorder.
Canadian courts struck down the disputed patents under the "promise doctrine," which Eli Lilly said violates NAFTA.
Under Canadian patent rules, a drug's usefulness must be demonstrated or soundly predicted as of the date the patent application is filed.
"Patent decisions in Canada over the last decade not only fly in the face of long-established international standards, but theyâ€™re subjective and completely unpredictable," said Doug Norman, Eli Lilly's general patent counsel.
"The standard seems to be that there is no standard."
The challenge comes amid ongoing debate regarding investor protection rights in Canada's trade agreements with China and Europe. Critics have raised concerns the trade deals will give foreign corporations the ability to challenge Canadian policy decisions.
The Department of Foreign Affairs, Trade and Development said Friday it was assessing the notice of arbitration.
"Our government's actions will continue to reflect our commitment to ensure Canadians continue to have access to the affordable drugs they need, while promoting innovation and job creation," spokeswoman Caitlin Workman said in a statement.
Richard Gold, a patent law professor at McGill University, said Eli Lilly has no grounds for its case.
"To me this is frivolous and vexatious and should really have never been put forward," he said.
Gold dismissed the company's assertion that Canada is unique and out of step with international standards, noting that Australia and New Zealand use similar patent rules, while the United States and Britain use different rules.
"There are no set of international norms. Many of us would like there to be international norms because it would make life a lot easier, but they don't exist," he said.
The Federal Court struck down Eli Lilly's patent for Strattera in 2010. The Federal Court of Appeal dismissed Eli Lilly's appeal in July 2011 and the Supreme Court of Canada denied leave to appeal that decision in December of that year.
The Zyprexa patent was first rendered invalid in October 2009 by the Federal Court, but that decision was overturned by the Federal Court of Appeal in July 2010.
However, the Federal Court invalidated the patent a second time in November 2011 and that decision withstood an appeal in September 2012. The Supreme Court denied leave to appeal in May of this year.
The request for arbitration, which will likely take years to resolve, follows a 90-day period of negotiations between the government and the company in an attempt to resolve the dispute.
Jim Keon, president of the Canadian Generic Pharmaceutical Association, said Eli Lilly overpromised and underdelivered.
"I think the suggestion that Canadian law is weak and out of step is incorrect," he said in an interview from Edmonton.
"Eli Lilly promised certain things in their patents that they could not demonstrate."
Read more Business News
|QHR Technologies Inc||1.20||-0.08|
|Anavex Life Sciences||0.37||-0.01|
|Copper Mountain Mining||1.56||+0.02|
This column is the last of three, for how to prove your personal injury claim. It is the piece de resistance of the trilogy, the Chuck Norris piece – the final say! As mentioned in the first two...
Recently I recorded a video series for my keynote speaking business. It was called from Faith to Future. In one of the episodes, I talked about the concept of using hard work to get out of a difficul...
The bank manager just phoned and asked for full and immediate repayment of the line of credit because the latest, (and they were late!), financial statements showed continuing losses and falling sales...
- Expert tells jury Warhol portrait of Fawcett at centre of dispute is worth $12 million
- Newfoundland premier will announce financing for $7.7B hydro project: sources
- Judge orders Colo. cake-maker to serve gay couples for wedding celebrations
- Custom offers, guidance as you walk around Apple stores with precise location technology
- Most actively traded companies on the TSX, TSX Venture Exchange markets
- Housing starts fall in November: CMHC
- Markets advance, strong U.S. jobs data competes with Fed tapering concerns
- Canadian dollar closes lower amid strong Canadian, U.S. jobs reports
- Google, Facebook, other major tech companies call for tighter controls on government snooping
- Canadian big banks post record profits in 2013, but outlook raises concern
- Ontario company to be sentenced in deadly Toronto propane plant blast
- Singer Bocelli visits MIT for workshop on adaptive technology for the visually impaired